UPCC 03820: A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors

The purpose of the study is to test the safety, anti-tumor activity, and the ability of an investigational drug called BMS-986179 plus nivolumab to block the protein CD73 from producing high amounts of a product known as adenosine which blocks the immune system from killing cancer cells. At our site we enroll subjects onto Part 2 of this study to test the dose and dose schedule that was previously identified. This study will be available to subjects with renal cell cancer (RCC).

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All